Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab

No abstract is available for this paper.

• Publication year

  2018

• Venue

  British Journal of Dermatology

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjd.15631PMID 28477389
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview

  2016cited by this paper
• Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study

  2016cited by this paper
• Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris

  2016cited by this paper
• Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

  2016cited by this paper
• Adverse reactions to biologic agents and their medical management

  2014cited by this paper
• Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists

  2014cited by this paper
• Induction or Exacerbation of Psoriasis in Patients with Crohn's Disease under Treatment with Anti-TNF Antibodies

  2014cited by this paper
• A case of ulcerative colitis complicating anti‐tumor necrosis factor treatment for rheumatoid arthritis: successful treatment with leukocytapheresis

  2013cited by this paper
• Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

  2013cited by this paper
• Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases.

  2013cited by this paper
• Exacerbation of Crohn's disease as paradoxical effect of infliximab.

  2012cited by this paper
• Role of biological therapy for inflammatory bowel disease in developing countries

  2012cited by this paper
• Paradoxical inflammation induced by anti-TNF agents in patients with IBD

  2012cited by this paper
• Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.

  2012cited by this paper
• Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors

  2012cited by this paper
• Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

  2012cited by this paper
• Ulcerative colitis.

  2011cited by this paper
• Role of biological therapy for inflammatory bowel disease in developing countries

  2011cited by this paper
• Psoriasis associated with ulcerative colitis and Crohn's disease

  2009cited by this paper
• Cross-regulation of TNF and IFN-¿ in autoimmune diseases

  2005cited by this paper
• Cross-regulation of TNF and IFN-alpha in autoimmune diseases.

  2005cited by this paper
• [Ulcerative colitis].

  1958cited by this paper

• T Cell‐Specific Deficiency of Src Homology 2‐Containing Protein Tyrosine Phosphatase 2 Ameliorates Psoriasis and Colitis by Promoting Treg Differentiation

  2025cites this paper
• Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis

  2025cites this paper
• Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real‐World Assessment

  2024cites this paper
• Clinical Study of Modified Yanghetang Combined with Mesalazine in Treating Ulcerative Colitis of Spleen-Kidney Yang Deficiency

  2024cites this paper
• Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab.

  2023cites this paper
• Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases

  2023cites this paper
• Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): A review on etiological and pathogenetic aspects.

  2021cites this paper
• Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases

  2021influential citation
• Psoriasis paradójica palmoplantar secundaria al tratamiento de la colitis ulcerosa con adalimumab

  2021cites this paper
• Adalimumab for Psoriasis

  2020cites this paper
• Reopening the case for case reports

  2020cites this paper
• Switching biologics in psoriasis - practical guidance and evidence to support

  2020cites this paper
• Secondary causes of inflammatory bowel diseases

  2020cites this paper
• Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review

  2020influential citation
• Ustekinumab Improves Paradoxical Enteropathy Associated With Psoriasis Arthritis.

  2019cites this paper
• Psoriasis and Inflammatory Bowel Disease

  2019cites this paper
• Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis

  2019influential citation
• Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.

  2018cites this paper
• Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature

  2018cites this paper
• Ulcerative colitis: yet another paradoxical effect of tumour necrosis factor blockers?

  2018cites this paper